Clinical trials: Bone Mass
Male Osteoporosis
Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis
This study will investigate if the drug zoledronic acid given once yearly is safe and has beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with osteoporosis.
- Trial name
- NCT00439647
- Testing
- Zoledronic acid 5 mg iv
- Where
- 128 sites in Argentina, Australia and 21 more
- Volunteers
- 1,199 people
- Sponsor
- Novartis Pharmaceuticals
Hypercalciuria, Hypercalciuria, Familial Idiopathic
The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass
The purpose of this study is to assess if estrogen replacement normalizes urinary calcium excretion in postmenopausal women with hypercalciuria and low bone mass and to assess for differences in response to estrogen replacement…
- Conditions
- Hypercalciuria, Hypercalciuria, Familial Idiopathic, Osteopenia, Osteoporosis
- Trial name
- NCT01928082
- Testing
- Transdermal estradiol
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Cancer, Cataract
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in men with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen deprivation…
- Conditions
- Cancer, Cataract, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00925600
- Testing
- Denosumab
- Where
- 172 sites in United States, Australia and 16 more
- Volunteers
- 769 people
- Sponsor
- Amgen
Postmenopausal, Osteopenia
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)
The primary objective of this study was to assess the safety, tolerability, and immunogenicity potential of romosozumab following multiple subcutaneous (SC) administrations in healthy men and postmenopausal women with low bone…
- Trial name
- NCT01825785
- Testing
- Romosozumab
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Amgen
Osteoporosis
A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects
The primary objective of this study is to assess the effect of AMG 162 (denosumab) treatment on the lumbar spine BMD at month 12 and safety profile across the dose range tested (14, 60 and 100 mg SC once every 6 months) in…
- Trial name
- NCT00306189
- Testing
- 100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162
- Volunteers
- 212 people
- Sponsor
- Amgen
Osteoporosis
Denosumab Adherence Preference Satisfaction Study
The primary objective is to evaluate the adherence of subjects to subcutaneous (SC) 60 mg denosumab every 6 months (Q6M) treatment compared to oral 70 mg alendronate once a week (QW) treatment at the end of treatment period 1 (12…
- Trial name
- NCT00518531
- Testing
- alendronate, denosumab
- Volunteers
- 250 people
- Sponsor
- Amgen
Primary Hyperparathyroidism, Parathyroid Adenoma
Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.
The only known cure for primary hyperparathyroidism is surgical removal of one or more parathyroid glands. Some patients however, do not fulfill criteria for surgery or do not want to undergo a procedure due to fear of the…
- Conditions
- Primary Hyperparathyroidism, Parathyroid Adenoma, Parathyroid Hyperplasia
- Trial name
- DENOCINA (NCT03027557)
- Testing
- Cinacalcet 30 mg Tablet, Denosumab Inj 60 mg/ml
- Where
- Denmark
- Volunteers
- 46 people
- Sponsor
- Peter Vestergaard
HIV Infections, Heart Disease
Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks
The hypothesis of this study is that 96 weeks of Rosuvastatin will be safe and effective in decreasing cardiovascular risk and bone loss in the HIV+ population.
- Trial name
- NCT01218802
- Testing
- Rosuvastatin 10 mg. daily for 96 weeks
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- University Hospitals Cleveland Medical Center
Anorexia Nervosa, Osteoporosis
The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa
Decreased bone strength is a common and serious medical problem present in many women with anorexia nervosa, or disordered eating.
- Trial name
- NCT00759772
- Testing
- Teriparatide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Massachusetts General Hospital
Marfan Syndrome
Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
Marfan syndrome is an inherited connective tissue disorder with morbidity and mortality from aortic dilation and dissection. The degree of aortic dilation and response to beta-blockade (standard of care) vary in adults with…
- Trial name
- NCT00723801
- Testing
- Atenolol, Losartan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Brigham and Women's Hospital
Hypoparathyroidism, DiGeorge Syndrome
Effects of PTH Replacement on Bone in Hypoparathyroidism
Hypoparathyroidism is a rare condition associated with a low level of parathyroid hormone (PTH) in the blood. Hypoparathyroidism can be genetic and show up in childhood, or it can occur later in life.
- Trial name
- NCT00395538
- Testing
- PTH 1-34
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Osteoarthritis, Arthritis
Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component
This is a monocentric, prospective, randomized clinical survey to verify if the periprosthetic remodelling brought about either the AMIStem or the Quadra femoral component is equivalent.
- Conditions
- Osteoarthritis, Arthritis, Avascular Necrosis, Fracture of the Femoral Neck or Head
- Trial name
- NCT01285843
- Testing
- Anterior Minimally Invasive Approach (AMIS)
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Medacta International SA
Osteoporosis, Osteopenia
Adding Phosphorus to Osteoporosis Drug Treatment
Osteoporosis causes bones to weaken and break more easily. Calcium and phosphorus are two minerals that are essential for normal bone formation.
- Trial name
- NCT00074711
- Testing
- Calcium carbonate, Calcium Phosphate
- Where
- United States
- Volunteers
- 241 people
- Sponsor
- Creighton University
Osteoporosis, Postmenopausal
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
This was a prospective, randomized, open-label, two arm phase III trial designed to evaluate the efficacy and safety of zoledronic acid in preventing bone loss in postmenopausal women with operable breast cancer who had received…
- Trial name
- NCT00332709
- Testing
- Letrozole, Zoledronic acid
- Where
- 23 sites in Germany
- Volunteers
- 83 people
- Sponsor
- Novartis
Osteopenia, Bone Turnover Markers
Effects of Physical Training on Bone Turnover and Quality of Life in Osteopenic Postmenopausal Women.
The aim of our research was to define both in vivo and in vitro whether and to what extent an high-impact exercise program would affect bone cell turnover and improve the QoL in osteopenic postmenopausal women.
- Conditions
- Osteopenia, Bone Turnover Markers, Quality of Life
- Trial name
- NCT03195517
- Testing
- Physical exercise
- Volunteers
- 33 people
- Sponsor
- University Of Perugia
Epilepsy, Bone Loss
Antiepileptic Drugs and Osteoporotic Prevention Trial
Study Design: (e.g., Controlled, Double-Blind, Randomized, Parallel): Randomized, double-blind, placebo controlled of a bisphosphonate in the prevention of bone loss associated with the use of antiepileptic drugs.
- Conditions
- Epilepsy, Bone Loss, Osteoporosis, Fractures
- Trial name
- ADOPT (NCT00869622)
- Testing
- Risedronate
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Boston VA Research Institute, Inc.
Osteoporosis, Osteopenia
Texture Analysis for Postmenopausal Osteoporosis
The purpose of this study is to determine if a new test for osteoporosis can be useful in monitoring treatment. We are studying a new method for examining the quality of bone by an experimental method of computerized analysis of…
- Trial name
- NCT00145977
- Testing
- Alendronate, Calcium Citrate, Vitamin D
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Chicago
Spinal Cord Injury
The Relationship Between Irisin and Bone Health in Individuals With Spinal Cord Injury
This study will examine the relationship between circulating irisin and bone health individuals with spinal cord injury. Additionally, this study seeks to examine the influence of muscle fiber type on circulating irisin and…
- Trial name
- IBSCI (NCT05319522)
- Testing
- Acute Exercise
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Bone Density, Low, Bone Loss
Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa
This protocol is a randomized, double-blind, placebo-controlled clinical trial which aims to investigate the effect of romosozumab on BMD in women with anorexia nervosa.
- Conditions
- Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders
- Trial name
- NCT04779216
- Testing
- Romosozumab Prefilled Syringe, Zoledronic acid 5 mg
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Karen Klahr Miller, MD
Osteoporosis
Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
The purpose of this study is to assess the effects of zoledronic acid administered at the same time with teriparatide compared to zoledronic acid alone and teriparatide alone on bone mineral density (BMD) gain in the lumbar spine…
- Trial name
- NCT00439244
- Testing
- Zoledronic acid, Teriparatide
- Where
- 33 sites in United States, Belgium and 2 more
- Volunteers
- 412 people
- Sponsor
- Novartis